Cargando…

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs

INTRODUCTION: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Kenji, Setogawa, Akira, Higa, Risako, Moriyama, Ryo, Wakakura, Masato, Tomita, Goji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280104/ https://www.ncbi.nlm.nih.gov/pubmed/22347794 http://dx.doi.org/10.2147/OPTH.S29062

Ejemplares similares

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%
por: Gross, Ronald L, et al.
Publicado: (2007)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa, Vital Paulino, et al.
Publicado: (2012)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis, Vassilios, et al.
Publicado: (2018)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue, Kenji, et al.
Publicado: (2012)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy
por: Lerner, Simon Fabian, et al.
Publicado: (2017)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue, Kenji, et al.
Publicado: (2014)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado, Ahmed Salah, et al.
Publicado: (2012)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue, Kenji, et al.
Publicado: (2015)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner, Harvey B, et al.
Publicado: (2012)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell, Joanna H, et al.
Publicado: (2014)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma
por: Wu, Hai Wei, et al.
Publicado: (2017)

A Comfort Survey of Timolol Hemihydrate 0.5% Solution Once or Twice Daily vs Timolol Maleate in Sorbate
por: Stewart, William C, et al.
Publicado: (2013)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano, Tadashi, et al.
Publicado: (2016)

Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
por: Inatani, Masaru, et al.
Publicado: (2023)

Infantile Hemangiomas with Minimal and Arrested Growth: Clinical Features and Treatment Outcomes with 0.5% Topical Timolol Maleate
por: Bae, Kyung-Nam, et al.
Publicado: (2021)

Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial
por: Russ, Heloisa Helena, et al.
Publicado: (2013)

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients
por: Aihara, Makoto, et al.
Publicado: (2017)

Effects of 0.5% Timolol Maleate Ophthalmic Solution on Heart Rate and Selected Echocardiographic Indices in Apparently Healthy Cats
por: Gunther‐Harrington, C.T., et al.
Publicado: (2016)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu, Yoshie, et al.
Publicado: (2015)

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
por: Pfeiffer, Norbert, et al.
Publicado: (2010)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
por: Moisseiev, Elad, et al.
Publicado: (2013)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Bell, Nicholas P, et al.
Publicado: (2010)

Effect of timolol maleate (0.5%) in the management of myopic regression post laser-assisted in-situ keratomileusis: Clinical and topographical outcomes
por: Singh, Aastha, et al.
Publicado: (2020)

Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
por: Kelly Rigollet, Jaime Pablo, et al.
Publicado: (2011)

Dielectric and Electric Properties of Ba(0.996)La(0.004)Ti(0.999)O(3) Ceramics Doped with Europium and Hafnium Ions
por: Adamczyk-Habrajska, Małgorzata, et al.
Publicado: (2022)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Shemesh, Gabi, et al.
Publicado: (2012)

Timing and Efficacy of 595-nm Pulsed-Dye Laser Combined with 0.5% Timolol Maleate Solution in the Treatment of Superficial Infantile Hemangiomas
por: Shi, Weikang, et al.
Publicado: (2021)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2012)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
por: Inoue, Kenji, et al.
Publicado: (2011)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Comparison of Latanoprost/Timolol with Carbonic Anhydrase Inhibitor and Dorzolamide/Timolol with Prostaglandin Analog in the Treatment of Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a1b4irp8j9d2kfoce7fn0miseb